Summary
This 8-K filing by AbbVie Inc. (ABBV) on October 2, 2020, primarily serves to make available pro forma financial information related to its previously completed acquisition of Allergan plc. The acquisition, finalized on May 8, 2020, was a significant strategic move for AbbVie. The filing details the partial funding of this acquisition through substantial debt issuances, including $30 billion in senior unsecured notes in November 2019 and approximately $13.7 billion and €2.5 billion in additional notes issued in May 2020 as part of exchange offers related to Allergan's former debt. The main purpose of this report is to provide investors with unaudited pro forma condensed combined financial statements. These statements present the combined earnings for the year ended December 31, 2019, and the six months ended June 30, 2020, as if the Allergan acquisition had occurred on those respective dates. While these pro forma figures are intended for informational purposes, they offer insight into the potential financial scale and impact of the combined entity, which is crucial for investors evaluating AbbVie's future performance and financial standing post-acquisition.
Key Highlights
- 1AbbVie completed the acquisition of Allergan plc on May 8, 2020.
- 2The acquisition was partially funded by significant debt issuances, including $30 billion in senior unsecured notes (November 2019) and approximately $13.7 billion/€2.5 billion in notes (May 2020) from exchange offers.
- 3The filing provides unaudited pro forma condensed combined financial information, giving effect to the Allergan acquisition.
- 4Pro forma statements of earnings are presented for the year ended December 31, 2019, and the six months ended June 30, 2020.
- 5This pro forma information is presented for informational purposes and illustrates the potential combined financial picture.
- 6AbbVie is also initiating registered exchange offers for the notes issued in connection with the acquisition.